In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Janssen Research Foundation

Division of Johnson & Johnson
www.janssen.com

Latest From Janssen Research Foundation

Start-Up Spotlight: GNS Healthcare Deploys Causal Algorithms To Drive Health Outcomes, Save Costs

GNS Healthcare wants to be on the forefront of the digital revolution in health care by offering its artificial intelligence powers to pharmaceutical and health-insurer customers to help them find the drivers of health outcomes and save costs along the way. It has also teamed up with research and patient foundations to expedite the R&D process, predict best treatment options for patients and create efficiencies for clinical trials.

Artificial Intelligence Commercial

Shire Shifts Upstream

Shire's latest acquisition, of Canada's BioChem Pharma, is its sixth in as many years, and the clearest sign yet of the shift which the UK-based specialty pharmaceutical company has to make towards earlier-stage research in order to keep up its impressive growth. Behind this growth is its low-risk Search & Development strategy: it seeks out promising, undervalued specialist-market drugs which it develops for new indications, or else finds new formulations for, after which it hands them on to its highly focused marketing and sales teams. A series of acquisitions-bolting on products, development programs and skills-has allowed Shire to quickly expand globally and broaden its portfolio. But as drugs get harder to find and more expensive, the company has had to throw its S&D net wider.
BioPharmaceutical Strategy

Maturing Business Models Using Genomics Data

Advice of Counsel addresses the question of whether genomics companies are using new business models and deal structures to commercialize their technologies.
BioPharmaceutical Strategy
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register